(Circulation. 1999;100:700-705.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors
From the Division of Infectious Diseases (D.P., A.T., P.H., M.P.G.), Department of Pediatrics (J.-J.C.), Division of Endocrinology (M.J.R.), Department of Medicine (P.N., V.M.), and Medical Policlinic (R.D.), CHUV University Hospital, Lausanne, Switzerland; the Swiss HIV Cohort Study (P.S.); and Northwest Lipid Research Laboratories, University of Washington (S.M.M.), Seattle, Wash.
Correspondence to Vincent Mooser, MD, Department of Medicine, BH 19-135, CHUV University Hospital, CH-1011 CHUV Lausanne, Switzerland. E-mail vincent.mooser{at}hola.hospvd.ch
Background—Administration of protease inhibitors (PIs) to HIV-infected individuals has been associated with hyperlipidemia. In this study, we characterized the lipoprotein profile in subjects receiving ritonavir, indinavir, or nelfinavir, alone or in combination with saquinavir.
Methods and Results—Plasma lipoprotein levels were quantified in 93 HIV-infected adults receiving PIs. Comparison was done with pretreatment values and with 28 nonPI-treated HIV-infected subjects. An elevation in plasma cholesterol levels was observed in all PI-treated groups but was more pronounced for ritonavir (2.0±0.3 mmol/L [mean±SEM], n=46, versus 0.1±0.2 mmol/L in nonPI treated group, P<0.001) than for indinavir (0.8±0.2 mmol/L, n=26, P=0.03) or nelfinavir (1.2±0.2 mmol/L, n=21, P=0.01). Administration of ritonavir, but not indinavir or nelfinavir, was associated with a marked elevation in plasma triglyceride levels (1.83±0.46 mmol/L, P=0.002). Plasma HDL-cholesterol levels remained unchanged. Combination of ritonavir or nelfinavir with saquinavir did not further elevate plasma lipid levels. A 48% increase in plasma levels of lipoprotein(a) was detected in PI-treated subjects with pretreatment Lp(a) values >20 mg/dL. Similar changes in plasma lipid levels were observed in 6 children receiving ritonavir.
Conclusions—Administration of PIs to HIV-infected individuals is associated with a marked, compound-specific dyslipidemia. The risk of pancreatitis and premature atherosclerosis due to PI-associated dyslipidemia remains to be established.
Key Words: AIDS • atherosclerosis • drugs • hyperlipoproteinemia • lipoproteins
This article has been cited by other articles:
 |
|
 |
|
  N. Obel, F. N Engsig, L. D Rasmussen, M. V Larsen, L. H Omland, and H. T Sorensen Cohort Profile: The Danish HIV Cohort Study Int. J. Epidemiol., October 1, 2009; 38(5): 1202 - 1206. [Full Text] [PDF]
|
|
|
|
 |
|
 A J Flammer, N T T Vo, B Ledergerber, F Hermann, A Gamperli, A Huttner, J Evison, I Baumgartner, M Cavassini, D Hayoz, et al. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial Heart, March 1, 2009; 95(5): 385 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pou, A. Rebollo, N. Roglans, R. M. Sanchez, M. Vazquez-Carrera, J. C. Laguna, J. Pedro-Botet, and M. Alegret Ritonavir Increases CD36, ABCA1 and CYP27 Expression in THP-1 Macrophages Experimental Biology and Medicine, December 1, 2008; 233(12): 1572 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Stein, C. M. Hadigan, T. T. Brown, E. Chadwick, J. Feinberg, N. Friis-Moller, A. Ganesan, M. J. Glesby, D. Hardy, R. C. Kaplan, et al. Prevention Strategies for Cardiovascular Disease in HIV-Infected Patients Circulation, July 8, 2008; 118(2): e54 - e60. [Full Text] [PDF]
|
|
|
|
|
|
C. Grunfeld, D. P. Kotler, D. K. Arnett, J. M. Falutz, S. M. Haffner, P. Hruz, H. Masur, J. B. Meigs, K. Mulligan, P. Reiss, et al. Contribution of Metabolic and Anthropometric Abnormalities to Cardiovascular Disease Risk Factors Circulation, July 8, 2008; 118(2): e20 - e28. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Dekhtyar, T. I. Ng, L. Lu, S. Masse, D. A. DeGoey, W. J. Flosi, D. J. Grampovnik, L. L. Klein, D. J. Kempf, and A. Molla Characterization of a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, A-790742 Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1337 - 1344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Eugenin, S. Morgello, M. E. Klotman, A. Mosoian, P. A. Lento, J. W. Berman, and A. D. Schecter Human Immunodeficiency Virus (HIV) Infects Human Arterial Smooth Muscle Cells in Vivo and in Vitro: Implications for the Pathogenesis of HIV-Mediated Vascular Disease Am. J. Pathol., April 1, 2008; 172(4): 1100 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kratz, J. Q. Purnell, P. A. Breen, K. K. Thomas, K. M. Utzschneider, D. B. Carr, S. E. Kahn, J. P. Hughes, E. A. Rutledge, B. Van Yserloo, et al. Reduced Adipogenic Gene Expression in Thigh Adipose Tissue Precedes Human Immunodeficiency Virus-Associated Lipoatrophy J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 959 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. May, J. A C Sterne, M. Shipley, E. Brunner, R. d'Agostino, P. Whincup, Y. Ben-Shlomo, A. Carr, B. Ledergerber, J. D Lundgren, et al. A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men Int. J. Epidemiol., December 1, 2007; 36(6): 1309 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Triant, H. Lee, C. Hadigan, and S. K. Grinspoon Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2506 - 2512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Kerr, C. Duncombe, A. Avihingsanon, J. Ananworanich, M. Boyd, B. Sopa, B. Medtech, T. Chuenyam, D. A. Cooper, J. M.A. Lange, et al. Dyslipidemia in an Asian Population After Treatment for Two Years With Protease Inhibitor-Containing Regimens J Int Assoc Physicians AIDS Care (Chic Ill), March 1, 2007; 6(1): 36 - 46. [Abstract] [PDF]
|
|
|
|
 |
|
 J. S. Currier and L. R. Baden Getting Smarter -- The Toxicity of Undertreated HIV Infection N. Engl. J. Med., November 30, 2006; 355(22): 2359 - 2361. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jerico, H. Knobel, N. Calvo, M. L. Sorli, A. Guelar, J. L. Gimeno-Bayon, P. Saballs, J. L. Lopez-Colomes, and J. Pedro-Botet Subclinical Carotid Atherosclerosis in HIV-Infected Patients: Role of Combination Antiretroviral Therapy Stroke, March 1, 2006; 37(3): 812 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Hurlimann, R Chenevard, F Ruschitzka, M Flepp, F Enseleit, M Bechir, R Kobza, J Muntwyler, B Ledergerber, T F Luscher, et al. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial Heart, January 1, 2006; 92(1): 110 - 112. [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Restrepo, L. Diethelm, J. A. Lemos, E. Velasquez, T. A. Ovella, S. Martinez, J. Carrillo, and D. F. Lemos Cardiovascular Complications of Human Immunodeficiency Virus Infection RadioGraphics, January 1, 2006; 26(1): 213 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Wanke, J. Gerrior, K. Hendricks, J. McNamara, and E. Schaefer Alterations in Lipid Profiles in HIV-Infected Patients Treated With Protease Inhibitor Therapy Are Not Influenced by Diet Nutr Clin Pract, December 1, 2005; 20(6): 668 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Weber Killing Two Birds With One Stone: Targeting Chemokine Receptors in Atherosclerosis and HIV Infection Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2448 - 2450. [Full Text] [PDF]
|
|
|
|
|
|
E. J.A. van Wanrooij, H. Happe, A. D. Hauer, P. de Vos, T. Imanishi, H. Fujiwara, T. J.C. van Berkel, and J. Kuiper HIV Entry Inhibitor TAK-779 Attenuates Atherogenesis in Low-Density Lipoprotein Receptor-Deficient Mice Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2642 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Scott Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients Am. J. Health Syst. Pharm., April 15, 2005; 62(8): 809 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Stein, M. A. Merwood, J. B. Bellehumeur, P. E. McBride, D. A. Wiebe, and J. M. Sosman Postprandial Lipoprotein Changes in Patients Taking Antiretroviral Therapy for HIV Infection Arterioscler Thromb Vasc Biol, February 1, 2005; 25(2): 399 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Grinspoon and A. Carr Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults N. Engl. J. Med., January 6, 2005; 352(1): 48 - 62. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jerico, H. Knobel, M. Montero, J. Ordonez-Llanos, A. Guelar, J. L. Gimeno, P. Saballs, J. L. Lopez-Colomes, and J. Pedro-Botet Metabolic Syndrome Among HIV-Infected Patients: Prevalence, characteristics, and related factors Diabetes Care, January 1, 2005; 28(1): 132 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Cahn, J. M. Gatell, K. Squires, L. D. Percival, P. J. Piliero, I. A. Sanne, S. Shelton, A. Lazzarin, L. Odeshoo, T. D. Kelleher, et al. Atazanavir--A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical Trials J Int Assoc Physicians AIDS Care (Chic Ill), July 1, 2004; 3(3): 92 - 98. [Abstract] [PDF]
|
|
|
|
 |
|
 B. S Conklin, W. Fu, P. H Lin, A. B Lumsden, Q. Yao, and C. Chen HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries Cardiovasc Res, July 1, 2004; 63(1): 168 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Geyer, J. L. MacGregor, L. P. Fox, A. Rabinowitz, and D. Engler Eruptive Xanthomas Associated With Protease Inhibitor Therapy Arch Dermatol, May 1, 2004; 140(5): 617 - 618. [Full Text] [PDF]
|
|
|
|
|
|
P. Y. Hsue, J. C. Lo, A. Franklin, A. F. Bolger, J. N. Martin, S. G. Deeks, and D. D. Waters Progression of Atherosclerosis as Assessed by Carotid Intima-Media Thickness in Patients With HIV Infection Circulation, April 6, 2004; 109(13): 1603 - 1608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. B. Kinlaw and B. Marsh Adiponectin and HIV-Lipodystrophy: Taking HAART Endocrinology, February 1, 2004; 145(2): 484 - 486. [Full Text] [PDF]
|
|
|
|
|
|
A. Xu, S. Yin, L. Wong, K. Weng Chan, and K. S. L. Lam Adiponectin Ameliorates Dyslipidemia Induced by the Human Immunodeficiency Virus Protease Inhibitor Ritonavir in Mice Endocrinology, February 1, 2004; 145(2): 487 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Calza, R. Manfredi, and F. Chiodo Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients J. Antimicrob. Chemother., January 1, 2004; 53(1): 10 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fisac, N. Virgili, E. Ferrer, M. J. Barbera, E. Fumero, C. Vilarasau, and D. Podzamczer A Comparison of the Effects of Nevirapine and Nelfinavir on Metabolism and Body Habitus in Antiretroviral-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Controlled Study J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5186 - 5192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Nolan, G.F. Watts, S.E. Herrmann, M.A. French, M. John, and S. Mallal Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? QJM, November 1, 2003; 96(11): 825 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Barbaro HIV infection, highly active antiretroviral therapy and the cardiovascular system Cardiovasc Res, October 15, 2003; 60(1): 87 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tran, S. Robinson, I. Mikhailenko, and D. K. Strickland Modulation of the LDL receptor and LRP levels by HIV protease inhibitors J. Lipid Res., October 1, 2003; 44(10): 1859 - 1869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Petit, M. Duong, E. Florentin, L. Duvillard, P. Chavanet, J. M. Brun, H. Portier, P. Gambert, and B. Verges Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study J. Lipid Res., September 1, 2003; 44(9): 1692 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Reeds, B. Mittendorfer, B. W. Patterson, W. G. Powderly, K. E. Yarasheski, and S. Klein Alterations in lipid kinetics in men with HIV-dyslipidemia Am J Physiol Endocrinol Metab, September 1, 2003; 285(3): E490 - E497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B D Prendergast HIV AND CARDIOVASCULAR MEDICINE Heart, July 1, 2003; 89(7): 793 - 800. [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Riddler, E. Smit, S. R. Cole, R. Li, J. S. Chmiel, A. Dobs, F. Palella, B. Visscher, R. Evans, and L. A. Kingsley Impact of HIV Infection and HAART on Serum Lipids in Men JAMA, June 11, 2003; 289(22): 2978 - 2982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. S. Leow, C. L. Addy, and C. S. Mantzoros Human Immunodeficiency Virus/Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome: Clinical Presentation, Pathophysiology, and Therapeutic Strategies J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1961 - 1976. [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Woerle, P. R. Mariuz, C. Meyer, R. C. Reichman, E. M. Popa, J. M. Dostou, S. L. Welle, and J. E. Gerich Mechanisms for the Deterioration in Glucose Tolerance Associated With HIV Protease Inhibitor Regimens Diabetes, April 1, 2003; 52(4): 918 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dybul, M. Daucher, M. A. Jensen, C. W. Hallahan, T.-W. Chun, M. Belson, B. Hidalgo, D. C. Nickle, C. Yoder, J. A. Metcalf, et al. Genetic Characterization of Rebounding Human Immunodeficiency Virus Type 1 in Plasma during Multiple Interruptions of Highly Active Antiretroviral Therapy J. Virol., March 1, 2003; 77(5): 3229 - 3237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. DePAOLA Managing the care of patients infected with bloodborne diseases J Am Dent Assoc, March 1, 2003; 134(3): 350 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Carrillo-Jimenez, G. A. Lamas, and C. H. Hennekens Thiazolidinediones Could Improve Endothelial Dysfunction and Risk of Premature Coronary Heart Disease in HIV-Infected Patients Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2002; 7(4): 207 - 210. [Abstract] [PDF]
|
|
|
|
 |
|
 B. R. Schackman, K. A. Freedberg, M. C. Weinstein, P. E. Sax, E. Losina, H. Zhang, and S. J. Goldie Cost-effectiveness Implications of the Timing of Antiretroviral Therapy in HIV-Infected Adults Arch Intern Med, November 25, 2002; 162(21): 2478 - 2486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chen, A. Misra, and A. Garg Lipodystrophy in Human Immunodeficiency Virus-Infected Patients J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4845 - 4856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-s. Zhong, X.-h. Lu, B. S. Conklin, P. H. Lin, A. B. Lumsden, Q. Yao, and C. Chen HIV Protease Inhibitor Ritonavir Induces Cytotoxicity of Human Endothelial Cells Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1560 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Riddle, N. M. Schildmeyer, C. Phan, C. J. Fichtenbaum, and D. Y. Hui The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice J. Lipid Res., September 1, 2002; 43(9): 1458 - 1463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Mehta, I. A. Khan, R. N. Mehta, and R. M. Gowda Acute Coronary Syndrome in Patients with Human Immunodeficiency Virus Disease Angiology, September 1, 2002; 53(5): 545 - 549. [Abstract] [PDF]
|
|
|
|
|
|
P. G. Yeni, S. M. Hammer, C. C. J. Carpenter, D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, et al. Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel JAMA, July 10, 2002; 288(2): 222 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Rodondi, R. Darioli, A.-A. Ramelet, D. Hohl, V. Lenain, J. Perdrix, V. Wietlisbach, W. F. Riesen, T. Walther, L. Medinger, et al. High Risk for Hyperlipidemia and the Metabolic Syndrome after an Episode of Hypertriglyceridemia during 13-cis Retinoic Acid Therapy for Acne: A Pharmacogenetic Study Ann Intern Med, April 16, 2002; 136(8): 582 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Evaluation and Management of Dyslipidemia in HIV-Infected Patients AIDS Clinical Care, December 1, 2001; 2001(1201): 6 - 6. [Full Text]
|
|
|
|
 |
|
 M. Dybul, T.-W. Chun, C. Yoder, B. Hidalgo, M. Belson, K. Hertogs, B. Larder, R. L. Dewar, C. H. Fox, C. W. Hallahan, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters PNAS, November 29, 2001; (2001) 261568398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Lo, K. Mulligan, M. A. Noor, J.-M. Schwarz, R. A. Halvorsen, C. Grunfeld, and M. Schambelan The Effects of Recombinant Human Growth Hormone on Body Composition and Glucose Metabolism in HIV-Infected Patients with Fat Accumulation J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3480 - 3487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shahmanesh, H. Jaleel, Y. DeSilva, J. D C Ross, M. Caslake, and R. Cramb Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype Sex Transm Inf, August 1, 2001; 77(4): 283 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Stein, M. A. Klein, J. L. Bellehumeur, P. E. McBride, D. A. Wiebe, J. D. Otvos, and J. M. Sosman Use of Human Immunodeficiency Virus-1 Protease Inhibitors Is Associated With Atherogenic Lipoprotein Changes and Endothelial Dysfunction Circulation, July 17, 2001; 104(3): 257 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rietschel, C. Hadigan, C. Corcoran, T. Stanley, G. Neubauer, J. Gertner, and S. Grinspoon Assessment of Growth Hormone Dynamics in Human Immunodeficiency Virus-Related Lipodystrophy J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 504 - 510. [Abstract] [Full Text]
|
|
|
|
|
|
E. Bonnet, J.-B. Ruidavets, J. Tuech, J. FerriÈres, X. Collet, J. Fauvel, P. Massip, and B. Perret Apoprotein C-III and E-Containing Lipoparticles Are Markedly Increased in HIV-Infected Patients Treated with Protease Inhibitors: Association with the Development of Lipodystrophy J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 296 - 302. [Abstract] [Full Text]
|
|
|
|
 |
|
 J.J. Monsuez, B. Gallet, L. Escaut, F. Vayre, J.C. Charniot, M. Pulik, M Merad, C. Minozzi, M. Slama, S. Weber, et al. Clinical outcome after coronary events in patients treated with HIV-protease inhibitors Eur. Heart J., December 2, 2000; 21(24): 2079 - 2080. [PDF]
|
|
|
|
|
|
J. M. Lenhard, D. K. Croom, J. E. Weiel, and D. A. Winegar HIV Protease Inhibitors Stimulate Hepatic Triglyceride Synthesis Arterioscler Thromb Vasc Biol, December 1, 2000; 20(12): 2625 - 2629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hadigan, C. Corcoran, S. Piecuch, W. Rodriguez, and S. Grinspoon Hyperandrogenemia in Human Immunodeficiency Virus-Infected Women with the Lipodystrophy Syndrome J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3544 - 3550. [Abstract] [Full Text]
|
|
|
|
|
|
V. Mooser, M. M. Berger, L. Tappy, C. Cayeux, S. M. Marcovina, R. Darioli, P. Nicod, and R. Chiolero Major Reduction in Plasma Lp(a) Levels During Sepsis and Burns Arterioscler Thromb Vasc Biol, April 1, 2000; 20(4): 1137 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dowell, C. Flexner, P. O. Kwiterovich, and M. D. Lane Suppression of Preadipocyte Differentiation and Promotion of Adipocyte Death by HIV Protease Inhibitors J. Biol. Chem., December 22, 2000; 275(52): 41325 - 41332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Riddle, D. G. Kuhel, L. A. Woollett, C. J. Fichtenbaum, and D. Y. Hui HIV Protease Inhibitor Induces Fatty Acid and Sterol Biosynthesis in Liver and Adipose Tissues Due to the Accumulation of Activated Sterol Regulatory Element-binding Proteins in the Nucleus J. Biol. Chem., September 28, 2001; 276(40): 37514 - 37519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dybul, T.-W. Chun, C. Yoder, B. Hidalgo, M. Belson, K. Hertogs, B. Larder, R. L. Dewar, C. H. Fox, C. W. Hallahan, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters PNAS, December 18, 2001; 98(26): 15161 - 15166. [Abstract] [Full Text] [PDF]
|
|